NASDAQ: TXMDTherapeuticsmd Inc Stock
$3.86+0.02 (+0.52%)
Updated May 26, 2023
TXMD Price
$3.86
Fair Value Price
$6.76
Market Cap
$38.42M
52 Week Low
$3.25
52 Week High
$11.69
P/E
0.22x
P/B
1.2x
P/S
0.72x
PEG
N/A
Dividend Yield
N/A
Revenue
$51.05M
Earnings
$157.42M
Gross Margin
106.8%
Operating Margin
280.24%
Profit Margin
308.4%
Debt to Equity
0.86
Operating Cash Flow
-$8M
Beta
1.35
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TXMD Overview
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TXMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TXMD ($3.86) is undervalued by 42.93% relative to our estimate of its Fair Value price of $6.76 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
TXMD ($3.86) is significantly undervalued by 42.93% relative to our estimate of its Fair Value price of $6.76 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
TXMD is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TXMD due diligence checks available for Premium users.
Be the first to know about important TXMD news, forecast changes, insider trades & much more!
TXMD News
Valuation
TXMD fair value
Fair Value of TXMD stock based on Discounted Cash Flow (DCF)
Price
$3.86
Fair Value
$6.76
Undervalued by
42.93%
TXMD ($3.86) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TXMD ($3.86) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TXMD is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TXMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.22x
Industry
14.7x
Market
54.23x
TXMD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TXMD is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
TXMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.2x
Industry
1.74x
TXMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TXMD's financial health
Profit margin
Revenue
$416.0k
Net Income
-$3.6M
Profit Margin
-866.1%
TXMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TXMD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$59.6M
Liabilities
$27.6M
Debt to equity
0.86
TXMD's short-term assets ($24.74M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TXMD's short-term assets ($24.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TXMD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TXMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$33.2M
Investing
$0.0
Financing
$1.1M
TXMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TXMD vs Pharmaceutical Stocks
Therapeuticsmd Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.